Subjects aged 18 to 75 years with anxiety symptoms are enrolled in the study. Credit: Ground Picture / Shutterstock.

Mind Medicine has concluded the enrolment of 198 patients and dosing in the Phase IIb MMED008 clinical trial of MM-120 (lysergide D-tartrate) to treat generalised anxiety disorder (GAD).

The dose-optimisation, parallel, multi-centre, placebo-controlled, double-blind, randomised study is designed to compare the effect of different dosages of MM-120 against placebo in GAD patients.

Related Company Profiles

View all

Subjects aged 18 to 75 years with anxiety symptoms are included in the study.

They will be randomised to receive a single dose of 25µg, 50µg, 100µg or 200µg of MM-120, or placebo.

The primary goal of the study is to determine the dose-response relationship of four MM-120 doses compared with placebo.

It will be measured by the change in Hamilton Anxiety Rating Scale (HAM-A) from baseline to week four.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Key secondary objectives include assessments of tolerability, safety, anxiety symptoms, quality of life, and other measures of efficacy.

These assessments are measured up to 12 weeks after the single administration of MM-120.

Mind Medicine CEO and director Robert Barrow said: “Completion of enrolment of this study is a significant milestone for MindMed and moves us one step closer to our goal of transforming the treatment of GAD for the millions suffering from the disorder.

“Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enrol almost 200 participants in this trial in just over a year.

“We anticipate sharing topline results during the fourth quarter of this year.”